Global Herceptin Biosimilar Market to Surpass US$ 5.8 Billion by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global herceptin biosimilar market is estimated to be valued at US$ 1.3 billion in 2020 and is expected to exhibit a CAGR of 24.5 % over the forecast period (2020-2027).

Key Trends and Analysis of the Global Herceptin Biosimilar Market:

Key players are focused on obtaining product approvals to strengthen their position in the global herceptin biosimilar market. For instance, in June 2020, Roche Holding AG received the US Food Drug and Administration approval for Phesgo, a fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, a subcutaneous injection with combination with intravenous chemotherapy for treatment of early and metastatic breast cancer.

Moreover, key players are focused on launching products to strengthen their product portfolio in the global herceptin biosimilar market. For instance, in 2019, Samsungbioepis Co,.Ltd, received approval for its first oncology treatment, Ontruzant, a biosimilar of herceptin and received the approval from US Food Drug and Administration. The product is approved for treatment of metastatic HER2-overexpressing BC, early HER2-overexpressing BC, and advanced gastric cancer in the U.S.

Among regions, North America is expected to register highest growth rate due to the increasing prevalence of diseases such as colorectal cancer, breast cancer and lung cancer in women. The US National Library of Medicine’s report published in September 2020 stated that around breast, lung and colorectal cancer accounted for 50% of the overall cancer incidence in women in the US.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4258

Key Market Takeaways:

The global herceptin biosimilar market is expected to exhibit a CAGR of 24.5 % over the forecast period owing to the increasing prevalence of diseases such as gastric cancer and breast cancer in females and product approvals and launches in the global herceptin biosimilar market.

Competitive Landscape:

Key players operating in the global herceptin biosimilar market are Amgen Inc., AryoGen Biopharma, Biocon Limited, Celltrion Inc., Pfizer Inc., Merck & Co., Inc., Accord Healthcare Ltd, Gedeon Richter Plc, Genor Biopharma Company Ltd, Mabion SA, Mylan N.V, Roche Holding AG and Samsungbioepis Co,.Ltd.

Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4258

Market Segmentation:

  • Global Herceptin Biosimilar Market, By Indication:

    • Breast Cancer

    • Gastric Cancer

    • Others

  • Global Herceptin Biosimilar Market, By Distribution Channel :

    • Hospitals

    • Oncology Centers

    • Others

  • Global Herceptin Biosimilar Market, By Region:

    • North America

    • Latin America

      • By Country:

        • Brazil

        • Mexico

        • Argentina

        • Rest of Latin America

    • Europe

      • By Country:

        • Germany

        • U.K.

        • France

        • Italy

        • Spain

        • Russia

        • Rest of Europe

    • Asia Pacific

      • By Country:

        • China

        • India

        • Japan

        • Australia

        • South Korea

        • ASEAN

        • Rest of Asia Pacific

    • Middle East

      • By Country/Region:

        • GCC

        • Israel

        • Rest of Middle East

    • Africa

      • By Country/Region:

        • South Africa

        • Central Africa

        • North Africa

Related Market Intelligence Report:

Biosimilars Market, by Drug Class (Recombinant Human Growth Hormone, Granulocyte Colony-Stimulating Factor, Insulin, Anticoagulants, Fusion Proteins, Erythropoietin, Monoclonal Antibodies, Follitropin, and Others), by Therapy Type (Oncology, Immunology, Hematology, Hormone Therapy, Metabolic Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Specialty Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) –

Read more

Global Blood Ketone Meter Market to Surpass US$ 486.3 Million by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global blood ketone meter market is estimated to be valued at US$ 301.7 million in 2020 and is expected to exhibit a CAGR of 7.1% during the forecast period (2020-2027).

Key Trends and Analysis of the market:

The increasing number of product launches is expected to drive growth of the blood ketone meter market during the forecast period. For instance, in March 2020, EKF Diagnostics, the global in vitro diagnostics company, announced the launch of the U.S. FDA CLIA-waived β-ketone and glucose POC analyzer STAT-Site WB Analyzer in the U.S. market. This device is a new addition to its diabetes care portfolio in the U.S. The STAT-Site WB is a dual-use whole blood β-ketone and glucose meter for professional use in the management of diabetes.

Key manufacturers operating in the blood ketone meter market are engaged in developing more advanced products for the ease of diabetes patients. For instance, blood glucose & ketone testing meter by Foracare Inc., called FORA 6 Gtel, is a device that comes with 3G/4G connectivity. It can seamlessly transfer data to a TeleHealth System without the need for pairing it with a smartphone. With 5-Electrode Technology and strips made with gold, FORA 6 test strips ensure high accuracy and precision. It measures six parameters such as glucose, hematocrit, hemoglobin, β-ketone, total cholesterol, and uric acid in blood.

The global blood ketone meter market is expected to witness significant growth, owing to increasing partnerships and collaborations. For instance, in February 2020, the global diabetes nonprofit Beyond Type 1 announced a new collaboration with the National Association of School Nurses to create awareness about the warning signs of type 1 diabetes (T1D). With this new collaboration, awareness materials will be distributed to tens of thousands of school nurses nationally in the U.S. Moreover, Beyond Type 1 advocates will be enhancing efforts in ten target states: Arkansas, Connecticut, Florida, Massachusetts, New Jersey, North Carolina, Ohio, Oklahoma, Pennsylvania, and Texas.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/3498

Key Market Takeaways:

The global blood ketone meter market is expected to exhibit a CAGR of 7.1% during the forecast period (2020-2027), owing to the rising prevalence of type 1 diabetes worldwide. For instance, according to the National Diabetes Statistics Report by Centers for Disease Control and Prevention of 2017, around 1.25 million Americans suffered from type 1 diabetes and over 300,000 Canadians lived with type 1 diabetes in 2017. Furthermore, as per the same source, over 100,000 children in India and 50,000 children and adolescents in China were living with type 1 diabetes as of 2017.

Key players in the North America blood ketone meter market are focused on launching new products, which is expected to drive growth of the market during the forecast period. For instance, in March 2020, EKF Diagnostics launched the STAT-Site WB, a blood β-ketone and glucose meter in the U.S. The device is used for measuring ketone and for the management of diabetes.

Competitive Landscape:

Key players

Read more

Global IV Infusion Bottle Seals & Caps Market to Surpass US$ 124.9 Million by 2027, Says Coherent Market Insights (CMI)

According to Coherent Market Insights, the global IV infusion bottle seals & caps market is estimated to be valued at US$ 104.3 million in 2020 and is expected to exhibit a CAGR of 2.6% over the forecast period (2020-2027).

Key Trends and Analysis of the Global IV infusion bottle seals & caps Market:

Key trends in the market include rising incidence of multiple sclerosis, arthritis, congestive heart failure, increasing launches of IV products, launch of new programs, and adoption of expansion strategies by the companies.

Rising incidence of chronic diseases such as multiple sclerosis, arthritis, congestive heart failure, and some types of immune deficiency disorders is expected to drive demand for infusion therapies, thereby contributing to significant growth of the IV infusion bottle seals & caps market. For instance, according to the National Center for Biotechnology Information (NCBI), 2020, in the year 2017, globally, around 126 million people suffered from ischemic heart disease (1,655 per 100,000). Furthermore, according to the World Federation of Hemophilia (WFH) 2018 statistics, around 440,000 people suffered from hemophilia, of which around 173,000 people were diagnosed with hemophilia A or B in 2017, globally.

Moreover, rising launches of IV products, in order to address the healthcare needs is the major factor, which is expected to drive the market growth over the forecast period. For instance, in June 2029, Eurolife Healthcare, a manufacturer and distributor specialty Infusion & pharmaceuticals, launched Discport and Lifeport IV products in India. These products are the replacement to the currently used polypropylene bottles (FFS bottles).

Moreover, market players are involved in launching new programs for patient safety, in order to increase the use of IV therapy and this is expected to drive the market growth. For instance, in April 2019, Becton, Dickson and Company (BD) launched a new program for patient safety in hospitals, called as PRIME (Preventing Risks of Infections and Medication Errors in IV Therapy). PRIME was developed in partnership with the Joint Commission International (JCI) for patient safety and aimed to address the challenges in a hospital setting regarding medical safety and infection prevention.

Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4238

Key Market Takeaways:

The global IV infusion bottle seals & caps market is expected to exhibit a CAGR of 2.6% over the forecast period, owing to facility expansion of pharmaceutical plastic packaging, which is expected to drive the market growth. For instance, in May 2018, Gerresheimer, a manufacturer of specialist packaging for drugs, announced the expansion of its facility in the Brazil. The new Gerresheimer Anápolis plant has commenced production in the Brazilian state of Goiás, for the production of the entire range of plastic containers from PP, PE, and PET, along with the corresponding closures and caps.

Competitive Landscape:

Key players operating in the global IV infusion bottle seals & caps market include Cardinal Health Inc., Jiangsu changjiang Lids, Taiwan Hon Chuan Enterprise, PrasadMeditech, Winfield Laboratories Inc., Datwyler HoldingAG, Wuxi Qitian Medical Technology Co., Ltd, Medline Industries Inc., RENOLITSE, and B. Braun Medical Inc.

Read more